ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Johnson & Johnson tests 10 variants of coronavirus vaccine

Group eyes human trials in fall, utilizing Ebola and HIV knowledge

Johnson & Johnson's Dutch unit Janssen Vaccines & Prevention started development of a vaccine for the new coronavirus in January as soon as the genetic code became available.   © Reuters

NEW YORK -- Johnson & Johnson is leveraging its technologies used in the development of vaccines for Ebola, Zika, and HIV in a race to stop the spread of COVID-19, the illness caused by the new coronavirus. 

The deadly outbreak has galvanized researchers across the globe, and countries and companies are rushing find treatments and develop a vaccine as the death toll rises. On Tuesday, the Chinese government said an influenza medicine, Avigan, developed by a group company of Japan's Fujifilm Holdings, is effective against the coronavirus.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more